Irish biopharmaceutical company: Jazz Pharmaceuticals (JAZZ) (2003)

Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ) was founded in 2003 and is headquartered in Dublin, Ireland, with 885 full-time employees. It is a commercial biopharmaceutical company engaged in the identification, development and commercial application of pharmaceutical products.

Jazz Pharmaceuticals (JAZZ):

Jazz Pharmaceuticals is a professional biopharmaceutical company, mainly engaged in the participation, research and development and sales of various medical drugs in the United States, Europe and internationally. Jazz Pharmaceuticals products include:

1. Xyrem-used to treat patients with narcolepsy-cataplexy/narcolepsy (EDS) medication;
2. Erwinaze-used to treat acute lymphatic leukemia;
3. Defitelio-for the treatment and prevention of hepatic venous obstructive disease (VOD), a potentially fatal complication after hematopoietic stem cell transplantation (HSCT);
4. Prialt-used to treat severe chronic pain;
5. FazaClo LD-medication for schizophrenia;
6. FazaClo HD tablets;
7. Versacloz;
8. JZP-110-used to treat patients with narcolepsy (EDS)-clinical stage;
9. JZP-386-sodium oxybate product, modified deuterium analogue, used in the treatment of narcolepsy-clinical stage;
10. Asparec-for the treatment of acute lymphoblastic leukemia (ALL) and E. coli-aspartame allergy-Phase I clinical trial stage;
11. Defibrotide-for the treatment of severe hepatic venous obstructive disease (VOD)-clinical trial stage;
12. Leukotac-an anti-CD25 monoclonal antibody for the treatment of steroid-ineffective acute graft-versus-host reaction-Phase III clinical trial phase.

History of Jazz Pharmaceuticals (JAZZ):

• In 2003, Jazz Pharmaceuticals was established;
• In 2005, Jazz Pharmaceuticals acquired Orphan Medical and its product-Xyrem ® ;
• In 2007, Jazz Pharmaceuticals released Luvox CR ® ;
• On September 19, 2011, Jazz Pharmaceuticals agreed to the merger of Azur Pharma, and the transaction was completed in 2012, bringing the company a new product-Prialt ® ;
• In 2012, Jazz Pharmaceuticals acquired EUSA Pharma for US$650 million, including its products-Erwinaze ® /Erwinase ® ;
• In 2013, Jazz Pharmaceuticals and Concert Pharmaceuticals (NASDAQ:CNCE) agreed to develop JZP-386;
• In 2014, Jazz Pharmaceuticals acquired JZP-110 development rights from Aerial BioPharma;
• In 2014, Jazz Pharmaceuticals acquired Gentium for US$1 billion, including its product Defitelio ® (defibrotide);
• In 2014, Jazz Pharmaceuticals acquired the US patent right of Defitelio ® (defibrotide) from Sigma-Tau Pharma ;
• In 2015, Jazz Pharmaceuticals started a phase III clinical trial of JZP-110;
• On May 31, 2016, biopharmaceutical company Jazz announced the acquisition of pharmaceutical company Celator for US$1.5 billion to obtain its investigational drug for the treatment of acute myeloid leukemia. The transaction was completed in July of the same year.